Miraca Life Sciences Announces Significant Plans at the Annual Meeting for LUGPA

An increased presence at LUGPA 2013 provides an opportunity to showcase Miraca's new solutions for healthier patients, and a healthier practice.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Irving, TX (PRWEB) October 10, 2013

Miraca Life Sciences (MLS), the leading pathology services provider that collaborates to make patients and practices better, announced today that it will have a significant presence at the Annual Meeting for the Large Urology Group Practice Association (LUGPA), a conference offering roundtable discussions, hands-on training and health policy updates, on November 7-9 in Chicago, Illinois.

Visitors to MLS’ booth can learn about a new genomic testing protocol that will help Urologists guide better treatment decisions and determine outcomes in prostate cancer patients. MLS urologic pathologists can find evidence of important genetic abnormalities, called biomarkers, through sophisticated laboratory tests. Understanding the unique genetic profile of each prostate cancer patient helps clinicians more fully understand the scope and level of disease, and to optimize outcomes through a personalized therapy aligned with genetic responsiveness.

In addition, MLS will be presenting important information about forthcoming regulatory guidance and compliance. MLS technical directors will be available to help visitors to their booth avoid potential Medicare penalties in 2014 and successfully attest to Meaningful Use requirements. MLS technical directors can help LUGPA members prepare for Meaningful Use audits by ensuring adherence to CMS requirements and prepare for the revolution in medical billing, ICD10.

“Miraca Life Sciences has a responsibility to doctors and patients to deliver reliable, meaningful laboratory results because effective patient care stems from accurate interpretation and diagnosis, so we’ll be introducing an exciting innovation in genomic testing protocols,” said Rajal B. Shah, MD, Director of Urologic Pathology at MLS. “Two important genetic abnormalities: one characterized by loss of a protective gene known as PTEN and another by overexpression of the cancer- promoting gene ERG occur in a staggering 50-60 percent of prostate cancer patients. Miraca Life Sciences helps the clinicians more fully understand the scope and level of disease, and to optimize outcomes aligned with genetic responsiveness.”

LUGPA holds an annual meeting every fall to provide a forum for discussion between integrated urology groups on the issues they face including declining reimbursement, increased complexity of third party contracting, pressure for adoption of EMR systems and an increasingly burdensome legislative and regulatory environment at both the state and federal levels. The meeting offers roundtable discussions, hands-on training and health policy updates. This year’s meeting, “The Future of Independent Urology: Alive and Well” will be held at The Drake Hotel in Chicago, November 7-9.

###

About Miraca Life Sciences

Serving more than 3,500 patients each day, Miraca Life Sciences is a leader in providing an academic-caliber pathology laboratory with diagnostic services in the fields of dermatology, gastroenterology, hematology and urology. Building upon our experience with health IT, we also offer accessible technology solutions to assist healthcare professionals as they work towards accordance with Meaningful Use initiatives.

Miraca Life Sciences, a wholly-owned subsidiary of Japan-based Miraca Holdings Inc., employs a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It is part of our commitment: not only to scientific excellence, but to patients and practices.

About LUGPA

The Large Urology Group Practice Association (LUGPA) was established with the purpose of enhancing communication among large groups, allowing for benchmarking of operations, promoting quality clinical outcomes, developing new opportunities, and improving advocacy in the legislative and regulatory arenas. Active LUGPA members have 10 or more physicians in their group practices, and associate members have at least five, but fewer than 10, physicians in their group practices. LUGPA’s mission is to provide urological surgeons practicing within the context of integrated group practices the means to access resources, technology and management tools that will enable them to furnish all services needed to care for patients with acute and chronic illnesses of the genitourinary system in an efficient, cost-effective and clinically superior manner, while using data collection to create parameters that demonstrate quality and value to patients, vendors, third party payors, legislators, and regulatory agencies.


Contact

  • Linda Fisk
    Miraca Life Sciences
    +1 214-596-2262
    Email